101166-73-8

Basic information

• Product Name: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)
• Synonyms: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI);2-METHYLPYRIDINE-3-ACETONITRILE;(2-Methylpyridin-3-yl)acetonitrile;2-Methyl-3-pyridineacetonitrile;(2-Methyl-3-pyridinyl)acetonitrile
• CAS NO: 101166-73-8
• Molecular Formula: C8H8N2
• Molecular Weight: 132.16252
• Product Categories: PYRIDINE;Aromatics, Heterocycles, Intermediates, Metabolites & Impurities
• Mol File: 101166-73-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 136-137℃ (10 Torr)
• Flash Point: 99.9±8.3℃
• Appearance: /
• Density: 1.056±0.06 g/cm3 (20 ºC 760 Torr)
• Refractive Index: 1.5255 (589.3 nm 25℃)
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• PKA: 4.89±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)(101166-73-8)
• EPA Substance Registry System: 3-Pyridineacetonitrile,2-methyl-(6CI,9CI)(101166-73-8)

Safety Data

• Hazardous Substances Data: 101166-73-8(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Oil

Uses

(2-Methylpyridin-3-yl)acetonitrile is used in the preparation of pyridine analogues of vitamin B1.

Upstream product

• 773837-37-9 sodium cyanide 
• 120277-68-1 2-methyl-3-(chloromethyl)pyridine 
• 143-33-9 sodium cyanide 
• 1118-66-7 4-amino-3-penten-2-one 
• 1721-12-6 1-(2-methylpyridin-3-yl)ethanone 
• 31805-47-7 (2-methyl-[3]pyridyl)-acetic acid amide 

Downstream Products

• 1977-05-5 2-(2-methylpyridin-3-yl)ethanol 
• 504404-51-7 2-(2-methyl-[3]pyridyl)-ethylamine 
• 856833-61-9 bis-[2-(2-methyl-[3]pyridyl)-ethyl]-amine 

Relevant articles and documents

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia

Small-molecule inhibitors of hypoxia-inducible factor prolyl hydroxylases (HIF-PHs) are currently under clinical development as novel treatment options for chronic kidney disease (CKD) associated anemia. Inhibition of HIF-PH mimics hypoxia and leads to increased erythropoietin (EPO) expression and subsequently increased erythropoiesis. Herein we describe the discovery, synthesis, structure–activity relationship (SAR), and proposed binding mode of novel 2,4-diheteroaryl-1,2-dihydro-3H-pyrazol-3-ones as orally bioavailable HIF-PH inhibitors for the treatment of anemia. High-throughput screening of our corporate compound library identified BAY-908 as a promising hit. The lead optimization program then resulted in the identification of molidustat (BAY 85-3934), a novel small-molecule oral HIF-PH inhibitor. Molidustat is currently being investigated in clinical phase III trials as molidustat sodium for the treatment of anemia in patients with CKD.

Cyanoamidine P2X7 antagonists for the treatment of pain

Novel cyanoamidines compounds of formula (I) and (II) and their derivatives wherein R1-R12 are as defined in the specification act as antagonists of the P2X7 receptor. These compounds are particularly useful in the treatment of pain, inflammation and neurodegeneration states.